Exit Ranbaxy post Lipitor launch: Edelweiss
VP-Institutional Equities at Edelweiss Securities Manoj Garg says once the potential trigger plays out, it will be a good time to book profit on Ranbaxy, which is likely to generate $350-400 million in revenues in the six month exclusivity period after Lipitor launch.
